Biotechs test IPO market despite concerns over Kennedy’s health role

Q: How long will it take to read this news story?

The story "Biotechs test IPO market despite concerns over Kennedy’s health role" has 735 words across 27 sentences, which will take approximately 4 - 7 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Biotechs test IPO market despite concerns over Kennedy’s health role" was covered 11 hours ago by Financial Times, a news publisher based in United States.

Q: How trustworthy is 'Financial Times' news outlet?

Financial Times is a fully independent (privately-owned) news outlet established in 1888 that covers mostly markets, finance, and investing news. The outlet is headquartered in United States and publishes an average of 6 news stories per day. It's most recent story was published 11 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #23814439</li><li>URL: https://beamstart.com/news/biotechs-test-ipo-market-despite-17325132172617</li></ul>

Financial Times 11h ago

Biotechs test IPO market despite concerns over Kennedy’s health role - Financial Times

Quick Summary:

So far this year, there have been 26 listings for biotech companies, raising a combined $4.3bn, after two slow years of issuance for the sector.

The biotech sector is closely linked with changes in interest rates because of the need to raise debt to fund costly clinical trials.

Mike Perrone, a biotech analyst at investment bank RW Baird, said the election and the ensuing nomination of Kennedy, known as RFK Jr, had “changed things pretty materially”.